Stemline Therapeutics, Inc. clinical trials

Acquired by Menarini Group, Jun 10, 2020 · source ↗

The registry lists 23 studies whose lead sponsor is Stemline Therapeutics, Inc.. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 23 of 23. All Menarini Group studies →

• KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme MalignanciesNot yet recruitingNCT07873827Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerRecruitingNCT07766018Phase 2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingNCT05386108Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceRecruitingNCT06492616Phase 3

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A Non-interventional Study of Participants With BPDCN Treated With ChemotherapyRecruitingNCT07785180

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A Registry-study of ELZONRIS in Participants With BPDCNRecruitingNCT07785154

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerRecruitingNCT06638307Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian CancerRecruitingNCT07226427Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyActive, not recruitingNCT06456463Phase 2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingNCT05563220Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyActive, not recruitingNCT05596409Phase 2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerCompletedNCT03778931Phase 3

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid TumorsCompletedNCT02667873Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma MultiformeCompletedNCT02078648Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid TumorsTerminatedNCT05382936Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)CompletedNCT02268253Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic FunctionCompletedNCT06126575Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted after Stemline Therapeutics, Inc. became part of Menarini Group

• SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete RemissionTerminatedNCT02270463Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaCompletedNCT02113982Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaTerminatedNCT02661022Phase 1/2

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast CancerCompletedNCT03088527Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast CancerCompletedNCT02650817Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group

• A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerCompletedNCT02338349Phase 1

  Sponsor listed in the registry: Stemline Therapeutics, Inc. · First submitted before Stemline Therapeutics, Inc. became part of Menarini Group